Skip to main content

Table 2 Test with a standardized 500 calories mixed breakfast for 5 h: metabolic profile

From: Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study

Areas under the curve

Baseline

Nateglinide

p

Baseline

Rosiglitazone

p

After 4 months

After 4 months

Median

(25th–75th)

Median

(25th–75th)

Median

(25th–75th)

Median

(25th–75th)

Glucose (mg/dL × min)

 Total

52,455

(4668–60,140)

40,245

(35,468–48,125)

0.001

47,340

(41,770–57,240)

43,670

37,820–51,550

0.005

 Incremental

11,955

(9251–15,523)

9241

(8004–12,805)

0.005

12,620

(8216–16,070)

11,070

(7595–12,330)

0.035

Insulin (U/mL × min)

 Total

6454

(5561–9922)

9220

(5807–16,340)

0.008

6992

(5023–8584)

6120

4213–7590

0.099

 Incremental

4107

(3277–6917)

6442

(4255–12,038)

0.006

4051

(2566–5324)

3208

2658–4756

0.049

Proinsulin (pM × min)

 Total

15,460

(9841–27,613)

16,020

(10,705–30,395)

0.135

12,470

(10,230–24,500)

11,730

7823–18,830

0.033

 Incremental

8100

(5601–12,305)

9915

(6203–18,713)

0.03

6668

(5505–9680)

6263

4706–9455

0.107

Glucagon (pg/mL × min)

 Total

23,535

(21,070–27,958)

22,160

(19,023–27,795)

0.455

21,460

(16,470–27,140)

24,060

19,500–25,740

0.520

 Incremental

3565

(2739–5480)

3094

(2119–5031)

0.351

3647

(2039–4770)

3268

2344–4302

0.748

GLP1 (pM × min)

 Total

46,995

(36,463–53,685)

48,660

(36,773–56,098)

0.179

42,890

(32,640–56,060)

42,390

37,710–47,390

0.872

 Incremental

4140

(3125–5464)

4454

(2680–6693)

1.000

3840

(2065–6469)

4171

2491–5602

0.687

Triglicerides (mg/dL × min)

 Total

43,500

(30,578–64,283)

46,375

(35,430–61,880)

0.737

42,060

(32,320–54,510)

40,350

30,480–59,240

0.717

 Incremental

9353

(5474–15,643)

11,120

(9132–16,548)

0.218

10,080

(6660–13,170)

9106

3945–10,580

0.044

Free fat acids (mEq/L ×min)

 Total

85.4

(75.6–113.6)

98.0

(81.5–119.1)

0.263

105.9

(79.1–113.3)

70.5

52.7–80.0

0.007

Glucose/insulin ratio

 Total

6.55

(5.27–10.01)

4.37

(2.86–6.62)

0.001

7.32

(5.93–10.61)

6.87

5.62–10.39

0.629

 Incremental

2.57

(1.72–3.98)

1.69

(0.77–2.31)

0.001

2.70

(2.26–5.07)

2.78

1.48–4.45

0.398

Proinsulin/insulin ratio

 Total

2.47

(1.37–3.11)

1.65

(1.37–2.17)

0.028

2.2

(1.64–3.2)

2.06

1.36–2.44

0.107

 Incremental

1.93

(1.21–2.43)

1.51

(1.20–1.82)

0.044

1.84

(1.44–2.40)

1.62

1.37–2.42

0.469

Insulinogenic index

 

48.6

(29.1–80.6)

205.7

(80.0–541.1)

0.002

41.8

(26.3–101.9)

65.1

47.8–91.7

0.355

  1. Wilcoxon matched pairs tests were performed to compare the differences for each group before and after the 4 months of therapy
  2. Italic values indicate statistical significance at p < 0.05
  3. GLP-1 glucagon like peptide-1